Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy save search
Todays' Top-5
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
Published: 2023-12-07 (Crawled : 13:00) - globenewswire.com
SLDB | News M | $5.89 72.22% 41.94% 12M
|
Health Technology
|
| O: 15.25%
H: 0.0%
C: 0.0%
sgt-003 fda designation duchenne therapy
Visgenx and Charles River Announce Expansion of Gene Therapy Manufacturing Alliance
Published: 2023-12-07 (Crawled : 11:00) - prnewswire.com
CRL | News | $202.77 1.04% 0.0% 430K
|
Commercial Services
|
| O: 0.01%
H: 0.0%
C: 0.0%
expansion therapy
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program- IND filing expected in mid-2025 -
Published: 2023-12-06 (Crawled : 20:00) - biospace.com/
VYGR | $7.85 3.15% 3.06% 180K
|
Health Technology
|
| O: 2.16%
H: 0.0%
C: 0.0%
SGMO | $0.443 -1.14% -1.15% 850K
|
Health Technology
|
| O: -4.81%
H: 0.0%
C: 0.0%
NBIX M | $119.97 0.42% 0.42% 880K
|
Health Technology
|
| O: 3.02%
H: 0.0%
C: 0.0%
candidate expected sclerosis therapeutics therapy
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Published: 2023-12-06 (Crawled : 17:00) - biospace.com/
COYA | $7.27 0.41% 0.41% 64K
|
|
| O: -6.04%
H: 0.0%
C: 0.0%
sclerosis treatment collaboration commercialization therapy
Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners
Published: 2023-12-06 (Crawled : 15:30) - biospace.com/
ZOM | $0.1632 -3.6% 1.72% 3.4M
|
Miscellaneous
| Email alert
Add to watchlist
pulsevet association presentation meeting therapy
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
Published: 2023-12-06 (Crawled : 14:30) - invobioscience.com
INVO | $1.53 -6.71% -7.19% 240K
|
Health Technology
|
| O: 3.77%
H: 0.0%
C: 0.0%
partnership natural cell research therapeutics therapy
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
Published: 2023-12-06 (Crawled : 12:00) - globenewswire.com
VYGR | $7.85 3.15% 3.06% 180K
|
Health Technology
|
| O: 2.16%
H: 0.0%
C: 0.0%
SGMO | $0.443 -1.14% -1.15% 850K
|
Health Technology
|
| O: -4.81%
H: 0.0%
C: 0.0%
NBIX M | $119.97 0.42% 0.42% 880K
|
Health Technology
|
| O: 3.02%
H: 0.0%
C: 0.0%
candidate sclerosis program therapeutics therapy
Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
Published: 2023-12-05 (Crawled : 21:00) - prnewswire.com
NBIX M | $119.97 0.42% 0.42% 880K
|
Health Technology
|
| O: 3.02%
H: 0.0%
C: 0.0%
drug food designation therapy
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
Published: 2023-12-05 (Crawled : 14:30) - globenewswire.com
GTHX | $3.16 30.58% 23.42% 10M
|
Health Technology
|
| O: 9.78%
H: 0.0%
C: -8.91%
trilaciclib therapeutics therapy
Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System
Published: 2023-12-05 (Crawled : 12:30) - prnewswire.com
ARAY A | $2.64 -0.75% -0.76% 440K
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: 0.0%
radixact sales solution system therapy
Therapy Co. SPAC Investors Fight Del. Stock-Drop Suit Toss – Law360
Published: 2023-12-02 (Crawled : 04:20) - spacfeed.com
APXI | $11.11 0.0% 6
|
n/a
| Email alert
Add to watchlist
spac therapy
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
TOT | News | $48.3 0%
|
Energy Minerals
| Email alert
Add to watchlist
nrtx-1001 cell ongoing trial therapeutics therapy
Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for CVDs and orphan diseases is the major market trend- Technavio
Published: 2023-12-01 (Crawled : 08:00) - prnewswire.com
NVS | News 1 d | $95.93 -1.15% 0.0% 1.2M
|
Health Technology
|
| O: 0.87%
H: 0.0%
C: 0.0%
ORTX | $16.27 0.28% 0.28% 54K
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
GBIO | $1.765 6.33% 5.95% 670K
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: 0.0%
BIIB | News | $239.14 2.25% 2.2% 1.2M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
AMGN S | $271.33 0.74% 0.73% 2M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
ADAP | $0.5561 -0.96% -0.97% 340K
|
Health Technology
|
| O: -3.0%
H: 0.0%
C: 0.0%
ABEO | $4.76 4.61% 4.41% 270K
|
Health Technology
|
| O: -2.43%
H: 0.0%
C: 0.0%
research growing therapy market
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
Published: 2023-12-01 (Crawled : 08:00) - prnewswire.com
EXAS | News | $64.96 -0.31% -0.31% 930K
|
Health Technology
|
| O: -2.08%
H: 0.0%
C: 0.0%
breast symposium cancer sciences therapy
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
Published: 2023-11-30 (Crawled : 21:00) - prnewswire.com
EXAS | News | $64.96 -0.31% -0.31% 930K
|
Health Technology
|
| O: -2.08%
H: 0.0%
C: 0.0%
breast symposium cancer sciences therapy
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
MS | News 0 d | $80.35 1.18% -0.03% 5.3M
|
Finance
|
| O: 0.28%
H: 0.9%
C: 0.72%
ABBV | News | $147.97 1.09% 0.05% 7.2M
|
Health Technology
|
| O: -0.35%
H: 3.4%
C: 3.17%
IMGN M | $29.355 0.05% 0.05% 12M
|
Health Technology
|
| O: 81.82%
H: 0.0%
C: 0.0%
elahere abbvie cancer tumor acquire therapy
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
BNTC | $3.365 7.51% 6.98% 4.7K
|
Health Technology
|
| O: 0.63%
H: 8.29%
C: -0.63%
bb-301 candidate treatment biopharma trial therapy
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
GH M | $26.28 2.1% 2.05% 1M
|
Health Services
|
| O: 1.51%
H: 3.92%
C: -1.29%
disease breast health symposium biomarker cancer therapy
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Published: 2023-11-29 (Crawled : 00:00) - prnewswire.com
ALPMY | $12.15 0.99% 590K
|
Manufacturing
|
| O: 0.66%
H: 0.0%
C: -0.16%
PFE A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: 0.0%
women therapy hormone
Bionano Announces Publication Demonstrating Utility of OGM to Assess Genome Integrity of CRISPR-Edited Cells as Part of Gene Therapy Development
Published: 2023-11-29 (Crawled : 15:00) - globenewswire.com
BNGO | $1.505 -9.88% -10.96% 1.7M
|
Health Technology
|
| O: 5.23%
H: 0.0%
C: 0.0%
publication therapy
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
SLDB | News M | $5.89 72.22% 41.94% 12M
|
Health Technology
SVFD | News | $3.09 43.72% 30.42% 64M
|
FTEL | $2.04 43.66% 30.39% 110K
|
HPCO 4 | $0.4824 41.92% 29.54% 28M
|
ALGS | News | $0.6475 -5.06% 26.67% 2.1M
|
Health Technology
GTHX | $3.16 30.58% 23.42% 10M
|
Health Technology
KEQU | $22.5 27.62% 21.64% 24K
|
Producer Manufacturing
GSIT | $3.09 27.16% 21.36% 2.2M
|
Electronic Technology
SSKN P | $0.628 25.6% 20.38% 210K
|
Health Technology
GLUE | $3.66 22.82% 18.58% 510K
|
Professional, Scientific, and T...
Your saved searches
Save your searches and get alerts when important news are released.